Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
May 11 2022 - 7:00AM
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology
company focused on developing advanced therapies for autoimmune and
inflammatory diseases, today announced that two posters will be
presented at the American Thoracic Society (ATS) 2022 Annual
Meeting reporting results from the CORONET and CASCADE studies in
patients with COVID-19 pneumonia.
“We are pleased and proud that the CORONET and CASCADE studies
will be presented at this year’s ATS to contribute new insights
that may advance the scientific and clinical knowledge base of this
devastating virus that has impacted lives around the world,” said
Rachelle Jacques, President and CEO of Akari Therapeutics. “There
are still many unanswered questions about the roles of inflammation
and complement activation in COVID-19 and it’s important that we
contribute to work shedding light on indicators of progression to
severe disease and on potential interventions.”
The CORONET study evaluated compassionate use of investigational
nomacopan in the treatment of hospitalized COVID-19 pneumonia
patients in the U.S., and the CASCADE study in the UK explored
correlations between biomarkers and risk stratification categories
to help predict the subsets of COVID-19 pneumonia patients who have
a higher propensity to deteriorate clinically to more severe
disease.
CORONETTitle: Compassionate use of C5
inhibitor, nomacopan, potentially influenced the course and
progression of disease in COVID-19
pneumoniaType: PosterSession: C62
– Expanding Our Insight Into
COVID-19Date/Time: May 17, 2022, 11:15 a.m. -
1:15 p.m. PTLocation: Area D, Hall F (Moscone
Center), San Francisco, CA
CASCADETitle: Biomarker levels concur with a
risk stratification criteria in COVID-19 pneumonia; a role for a
prognostic tool for identification of clinical
deterioratorsType: PosterSession:
C62 – Expanding Our Insight Into
COVID-19Date/Time: May 17, 2022, 11:15 a.m. - 1:15
p.m. PTLocation: Area D, Hall F (Moscone Center),
San Francisco, CA
The posters will be available at
http://investor.akaritx.com/news-and-events/presentations following
the presentations.
About Akari TherapeuticsAkari Therapeutics, plc
(Nasdaq: AKTX) is a biotechnology company focused on developing
advanced therapies for autoimmune and inflammatory diseases.
Akari's lead asset, investigational nomacopan, is a bispecific
recombinant inhibitor of C5 complement activation and leukotriene
B4 (LTB4) activity. The Akari pipeline includes two late-stage
programs for bullous pemphigoid (BP) and thrombotic microangiopathy
(TMA), as well as earlier stage research and development programs
in eye and lung diseases with significant unmet need. For more
information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking
StatementsCertain statements in this press release
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies, and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies, and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations, or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control. Such risks and
uncertainties for our company include, but are not limited to:
needs for additional capital to fund our operations, our ability to
continue as a going concern; uncertainties of cash flows and
inability to meet working capital needs; an inability or delay in
obtaining required regulatory approvals for nomacopan and any other
product candidates, which may result in unexpected cost
expenditures; our ability to obtain orphan drug designation in
additional indications; risks inherent in drug development in
general; uncertainties in obtaining successful clinical results for
nomacopan and any other product candidates and unexpected costs
that may result therefrom; difficulties enrolling patients in our
clinical trials; our ability to enter into collaborative,
licensing, and other commercial relationships and on terms
commercially reasonable to us; failure to realize any value of
nomacopan and any other product candidates developed and being
developed in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; inability to
develop new product candidates and support existing product
candidates; the approval by the U.S. Food and Drug Administration
(FDA) and European Medicines Agency (EMA) and any other similar
foreign regulatory authorities of other competing or superior
products brought to market; risks resulting from unforeseen side
effects; risk that the market for nomacopan may not be as large as
expected; risks associated with the impact of the COVID-19
pandemic; inability to obtain, maintain and enforce patents and
other intellectual property rights or the unexpected costs
associated with such enforcement or litigation; inability to obtain
and maintain commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; unexpected cost increases and pricing
pressures and risks and other risk factors detailed in our public
filings with the Securities and Exchange Commission (SEC),
including our most recently filed Annual Report on Form 20-F filed
with the SEC. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release, and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
For more information
Investor Contact:Peter VozzoICR Westwicke(443)
213-0505peter.vozzo@westwicke.com
Media Contact:Sukaina Virji/ Maya BennisonConsilium Strategic
CommunicationsAkari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024